Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia (June and Q1–Q2 2022)

Thursday, July 28, 2022

In January–June 2022, Russia manufactured 366 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), up 28.4% from January–June 2021. In physical terms, the production volume was 2.14 billion packages, up 5.9% from the same period in 2021. If calculated in minimum dosage units (MDU), Russia produced 40.5 billion MDUs, up 3.3% from January–June 2021.

In June 2022, Russian manufacturers produced 54.9 billion rubles’ worth of pharmaceutical drugs, up 19.7% from June 2021, making it a five-month low. In physical terms, the growth rate was 7% in packages and 6.1% in MDUs. While these results are much worse than those a month earlier, the production volumes still grew, which could be deemed a success against the backdrop of an increased activity from March to May and the onset of the so-called “low” season.

The production of OTC drugs contributed to the growth rates in physical terms the most, having grown 14.4% over the year. At the same time. the production of prescription drugs dropped 2.7%, which is due to the average package growing. If calculated in MDUs, the growth rates are the same for both groups: 3.4% for OTC drugs and 3.3% for Rx drugs.

Ingakamf had the highest growth rates among the manufacturers of OTC drugs in January–June 2022; its production grew 21 times against January–June 2021. Lapis pencil contributed to the company’s growth rates the most, although it is difficult to be sure that the entire volume is used for medical purposes, since the product is a popular tool for validating jewelry. Usolpharm also had impressive growth rates (production grew 19.2 times), manufacturing 24 products, which is nearly five times as many as a year earlier. It’s Corvalol and Paracetamol contributed to the company’s growth rates the most. Charoit Farma is also worth mentioning—its production increased 18.2 times against January–June 2021. The company is the holder of the registration certificate for Prostosorb, manufactured at the facilities of Flora Kavkaza.

As for prescription drugs, Alvils Holding had the best growth rates (manufacture grew 85.3 times), thanks to Phosphoglicerr and Dexamethasone. Lekvalis increased its manufacture 12.9 times against January–June 2021, with Metformin and Pantoprazole contributing to the growth rates the most. However, both companies are outside the top 100. Among the larger manufacturers, Ruzpharma (top 40) increased its production 3.6 times thanks to the manufacture of antibiotic Ceftriaxone.

Pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (packages) and monetary terms (RUB, VAT included) (2017–2021, Q1–Q2 2022)